⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
globenewswire.com
AIM
AIM Sports Group Enhances AIM Sportsplex with Spiideo’s Advanced Automated Video Technology
businesswire.com
AIM
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
globenewswire.com
AIM
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
globenewswire.com
AIM
AIM ImmunoTech Announces Stock Dividend
globenewswire.com
AIM
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
prnewswire.com
ONCY
AVBP
MRUS
HALO
AIM
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
globenewswire.com
AIM
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
globenewswire.com
AIM
Impact Communications Clients Shine as 2025 ThinkAdvisor Luminaries Award Finalists
businesswire.com
ADVV
AIM
SYNTAX
OASIS
LIBRETTO
KWANTI
STRAIGHTLINE
ENCORE
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
globenewswire.com
AIM